CN101112466B - Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof - Google Patents
Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof Download PDFInfo
- Publication number
- CN101112466B CN101112466B CN2007100704156A CN200710070415A CN101112466B CN 101112466 B CN101112466 B CN 101112466B CN 2007100704156 A CN2007100704156 A CN 2007100704156A CN 200710070415 A CN200710070415 A CN 200710070415A CN 101112466 B CN101112466 B CN 101112466B
- Authority
- CN
- China
- Prior art keywords
- extract
- chloasma
- vitamin
- percent
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a compound composition for the treatment of chloasma and constipation and the application, which pertains to the technical field of the health care products of Chinese traditional patent medicine and the traditional Chinese medicine. The present invention contains the raw materials components with the following mix ratio by weight: 3 to 50 percent traditional Chinese medicine extract, 10 to 55 percent xylooligosaccharide, 4 to 20 percent grape seed extract, 2 to 20 percent soybean extract, 4 to 20 percent vitamin C and 4 to 20 percent of vitamin E. The presentinvention uses the conventional production process to carry out the extraction of the active ingredients, the conventional excipients are also added according to the mix ratio and the different formulations, and then the final product which can be tablets, granules or capsules is made by full mixing. The present invention is characterized by the synergistic effect of a plurality of components; the present invention uses the health care methods of regulating qi, activating blood circulation, regulating the functions of qi and blood, lubricating bowel and promoting defecation for the people group with hepatic qi stagnation and stagnation of blood stasis, which has significant efficacy and no toxicity or side effects for the prevention and treatment of chloasma and constipation diseases.
Description
Technical field
The invention belongs to Chinese patent medicine and Chinese medicine health care product technical field, be specifically related to a kind of compound for the treatment of chloasma and relieving constipation.
Background technology
In recent decades, the drug development of preventing and treating chloasma, constipation is rapid, for the prevention and the treatment of chloasma, constipation provides strong weapon.Though clinical Western medicine has certain curative effect, it is satisfied that effect is still owed, and the side effect of various degrees, and life-time service easily causes severe complications.Up to the present, do not find the ideal product of control primary disease as yet.There is the unique advantage of whole regulating functions of ZANG FU-organs Chinese medicine prevention chloasma, constipation aspect, and there is advantageous natural resources of Chinese medicinal materials in China simultaneously, so Chinese medicine is having wide prospect aspect treatment chloasma, the constipation.
Summary of the invention
The object of the invention is to overcome problems of the prior art, the choose reasonable material combination, and in conjunction with modern medicine and threpsology in the achievement in research aspect chloasma and the constipation, design provides a kind of technical scheme for the treatment of the compound of chloasma and relieving constipation.
Described a kind of compound for the treatment of chloasma and relieving constipation is characterized in that containing following material component: Chinese medicine extract, oligomeric xylose, Semen Vitis viniferae extract, soybean extract, vitamin C, vitamin E.
Described a kind of compound for the treatment of chloasma and relieving constipation is characterized in that containing following materials of weight proportions component: Chinese medicine extract 3-50%, oligomeric xylose 10-55%, Semen Vitis viniferae extract 4-20%, soybean extract 2-20%, vitamin C 4-20%, vitamin E 4-20%.
Described a kind of compound for the treatment of chloasma and relieving constipation is characterized in that containing following materials of weight proportions component: Chinese medicine extract 4-40%, oligomeric xylose 10-50%, Semen Vitis viniferae extract 8-19%, soybean extract 5-18%, vitamin C 5-16%, vitamin E 5-15%.
Described a kind of compound for the treatment of chloasma and relieving constipation is characterized in that containing following proportion raw material component: Chinese medicine extract 5-25%, oligomeric xylose 30-42%, Semen Vitis viniferae extract 12-18%, soybean extract 9-15%, vitamin C 6-12%, vitamin E 5-10%.
Described Chinese medicine extract is one or more the mixed extract in Flos Rosae Rugosae, Radix Angelicae Sinensis and the Radix Angelicae Dahuricae.
The described a kind of application of compound in preparation treatment chloasma and relieving constipation medicine or health food that prevents and treats chloasma and relieving constipation.
Described Semen Vitis viniferae extract active princlple is a procyanidin, and the soybean extract active princlple is a soybean isoflavone.
Utilizing conventional production process to carry out the extraction of active ingredient, according to said ratio, and add conventional adjuvant by different dosage form, make finished product after fully mixing, can be tablet, granule or capsule.
As when producing tablet: Flos Rosae Rugosae, the Radix Angelicae Dahuricae, Radix Angelicae Sinensis with recipe quantity, decoct with water secondary, collecting decoction filters, and filtrate decompression concentrates, precipitate with ethanol left standstill 24 hours, filters, and decompression filtrate recycling ethanol, drying under reduced pressure gets dry extract, pulverize, cross 80 mesh sieves, the powder that gets dry extract, standby.Other raw material and the corresponding auxiliary material of getting recipe quantity again are pregelatinized Starch, carboxymethylstach sodium, magnesium stearate etc., pulverize, excessively mix homogeneously behind 80 mesh sieves, mixed powder and dried cream powder are merged mix homogeneously, and spray adds 95% ethanol, makes soft material, 16 mesh sieves are granulated, drying, 14 mesh sieve granulate.Dried granule behind the granulate is put mixer and is added the lubricant mixing, and tabletting, oven dry are promptly.
The production method of other dosage forms, the adjuvant of interpolation and consumption also all belong to existing known technology, do not repeat them here.
The recommendation consumption of the present composition: 3.0g-9.0g/ people/sky, swallow or take after mixing it with water according to the different waters of dosage form.
The present invention is characteristics with many components synergism, and at stagnation of QI due to depression of the liver, the crowd of blood-stasis internal-depression adopts vital energy regualting and blood circulation-promoting, transfers smooth QI and blood, the health-care method of loosening bowel to relieve constipation, and to preventing and treating chloasma and the relieving constipation disease has significant curative effect, and without any toxic and side effects.
The specific embodiment
By the following examples the present invention is elaborated, and further specify beneficial effect of the present invention with animal and clinical trial example.
The tablet of embodiment 1:0.75g/ sheet
| Composition | Prescription 1 | Prescription 2 | Prescription 3 |
| Flos Rosae Rugosae, Radix Angelicae Sinensis, Radix Angelicae Dahuricae extract | 109g | - | - |
| Flos Rosae Rugosae, Radix Angelicae Sinensis extract | - | 90g | - |
| Flos Rosae Rugosae extract | - | - | 75g |
| Oligomeric xylose | 240g | 240g | 240g |
| Semen Vitis viniferae extract | 90g | 90g | 90g |
| Soybean extract | 75g | 75g | 75g |
| Vitamin C | 55g | 55g | 55g |
| Vitamin E | 45g | 45g | 45g |
| The amount of making | 1000 | 1000 | 1000 |
The capsule of embodiment 2:0.3g/ grain
| Composition | Prescription 1 | Prescription 2 | Prescription 3 |
| Flos Rosae Rugosae, Radix Angelicae Sinensis, Radix Angelicae Dahuricae extract | 100g | - | - |
| Flos Rosae Rugosae, Radix Angelicae Dahuricae extract | - | 80g | - |
| Radix Angelicae Sinensis extract | - | - | 65g |
| Oligomeric xylose | 50g | 50g | 50g |
| Semen Vitis viniferae extract | 30g | 30g | 30g |
| Soybean extract | 25g | 25g | 25g |
| Vitamin C | 25g | 25g | 25g |
| Vitamin E | 20g | 20g | 20g |
| The amount of making | 1000 | 1000 | 1000 |
The granule of embodiment 3:1.5g/ bag
| Composition | Prescription 1 | Prescription 2 | Prescription 3 |
| Flos Rosae Rugosae, Radix Angelicae Sinensis, Radix Angelicae Dahuricae extract | 120g | - | - |
| Radix Angelicae Sinensis, Radix Angelicae Dahuricae extract | - | 80g | - |
| Radix Angelicae Dahuricae extract | - | - | 50g |
| Oligomeric xylose | 440g | 440g | 440g |
| Semen Vitis viniferae extract | 200g | 200g | 200g |
| Soybean extract | 150g | 150g | 150g |
| Vitamin C | 100g | 100g | 100g |
| Vitamin E | 60g | 60g | 60g |
| Composition | Prescription 1 | Prescription 2 | Prescription 3 |
| The amount of making | 1000 bags | 1000 bags | 1000 bags |
Test example 1: toxicological test
One, acute toxicity test
1 materials and methods
Test sample: by embodiment 1 prescription 1 product that makes, crowd's recommended amounts 3.0g/ day is by adult 60kg body weight 0.05g/kgBW.
Sample treatment: take by weighing test sample 10g and add the pure water mixing to 20ml
Laboratory animal: ICR kind mice provides the qualified animal of SPE level (the moving word 01-4059 of the quality certification number doctor), each 10 of body weight 18-22g male and female by laboratory animal portion of the Capital University of Medical Sciences.
2 experimental techniques: the maximum tolerated dose method, dosage 10g/kgBW, per os is irritated stomach and is given, and irritates stomach amount 0.2ml/10gBW.Stopped eating 16 hours before irritating stomach, observed for 1 week continuously, and record animal poisoning symptom and death condition.
3 experimental results:
Body weight and death condition before and after the experiment
When giving test sample 10g/kgBW (be equivalent to recommended amounts 200 times), animal activity is all normal, and the hair color glossiness is good, does not find any symptom.
Conclusion: test sample is with the acute toxicity classification, true border innocuous substance.
Two, micronucleus test
1. materials and methods
Test sample: by embodiment 1 prescription 1 product that makes, crowd's recommended amounts 3.0g/ day is by adult 60kg body weight 0.05g/kgBW.
Sample treatment: take by weighing test sample 10g, 5.0g, 2.5g and add the pure water mixing respectively to 20ml.
Laboratory animal: ICR kind mice, provide the qualified animal of SPE level (the moving word 01-4059 of the quality certification number doctor) by laboratory animal portion of the Capital University of Medical Sciences, body weight 23-28g goes into each group, 10 of every treated animals, male and female half and half by body weight stratified random branch.
Dosage grouping: by acute toxinology experiment maximal dose 10g/kgBW is maximum dose level, below establishes 1//2 (5.0g/kgBW) and two dosage groups of 1/4 (2.5g/kgBW) respectively, and other establishes positive controls (cyclophosphamide 40mg/kg) and negative control group.
2. experimental technique: gave test sample continuously two days (24 hours at interval) after the last administration 6 hours, the dislocation of animal cervical vertebra is put to death, and gets bone marrow of sternum, film-making routinely, dyeing, microscopy.Every animal is observed 1000 PCE, and record contains micronucleus PCE number, calculates micronuclear rates.
3. experimental result
| Group | Number of animals (male Mus) | Observe the PCE number | Contain micronucleus PCE number | Micronuclear rates (‰) | PCE/RBC |
| 10.0g/kgBW | 5 | 5×1000 | 4 | 0.80 | 1.64±0.14 |
| 5.0g/kgBW) | 5 | 5×1000 | 5 | 1.00 | 1.67±0.19 |
| 2.5g/kgBW) | 5 | 5×1000 | 5 | 1.00 | 1.68±0.16 |
| Negative control group | 5 | 5×1000 | 5 | 1.00 | 1.68±0.13 |
| CP40mg/kgBW | 5 | 5×1000 | 152 | 30.40 | 1.48±0.10 |
| Group | Number of animals (female Mus) | Observe the PCE number | Contain micronucleus PCE number | Micronuclear rates (‰) | PCE/RBC |
| 10.0g/kgBW | 5 | 5×1000 | 5 | 1.00 | 1.67±0.15 |
| 5.0g/kgBW) | 5 | 5×1000 | 5 | 1.00 | 1.66±0.14 |
| 2.5g/kgBW) | 5 | 5×1000 | 4 | 0.80 | 1.71±0.17 |
| Negative control group | 5 | 5×1000 | 6 | 1.20 | 1.66±0.13 |
| CP40mg/kgBW | 5 | 5×1000 | 156 | 31.20 | 1.48±0.09 |
Conclusion: each dosage group is compared with negative control group, all finds no significant difference (P＞0.05), and positive controls is compared the difference (P＜0.01) that highly significant is arranged with negative control group.Experimental result shows that in this test dose scope, this test sample does not bring out the increase of micronuclear rates.
Three, spermatic aberration test
1. materials and methods
Test sample: by embodiment 1 prescription 1 product that makes, crowd's recommended amounts 3.0g/ day is by adult 60kg body weight 0.05g/kgBW.
Sample treatment: take by weighing test sample 10g, 5.0g, 2.5g and add the pure water mixing respectively to 20ml.
Laboratory animal: male ICR kind SPF level mice, provide the qualified animal of SPE level (the moving word 01-4059 of the quality certification number doctor) by laboratory animal portion of the Capital University of Medical Sciences, body weight 23-28g goes into each group, 5 of every treated animals by body weight stratified random branch.
Dosage grouping: by acute toxinology experiment maximal dose 10g/kgBW is maximum dose level, below establishes 1/2 (5.0g/kgBW) and two dosage groups of 1/4 (2.5g/kgBW) respectively, and other establishes positive controls (cyclophosphamide 40mg/kg) and negative control group.
2. experimental technique: put to death in the 35th day after giving test sample continuously and giving for the first time in five days, and got two epididymises film-making dyeing and microscopies routinely surveyed, every animal is observed 1000 sperms, and record distortion sperm count calculates aberration rate.
3. experimental result
Conclusion: detect each dosage group through sum of ranks and compare with negative control group, all find no significant difference (P＞0.05), positive controls is compared the difference (P＜0.01) that highly significant is arranged with negative control group.Experimental result shows this test sample in this test dose scope, and not finding has mutagenesis to sexual cell.
Four, Salmonella reversion test
1. materials and methods
Test sample: by embodiment 1 prescription 1 product that makes, crowd's recommended amounts 3.0g/ day is by adult 60kg body weight 0.05g/kgBW.
Sample treatment: take by weighing test sample 1g, be dissolved in the sterilized water, insoluble part is dissolved among the DMSO again, will be settled to 20ml behind the two mixing as 5mg/ ware dosage, below respectively by 1 times, 5 times, 10 times, 50 times dilutions.
Test dose: test dose is chosen to be 5mg/ ware, 2.5mg/ ware, 1.0mg/ ware, 0.5mg/ ware, 5 dosage of 0.1mg/ ware.Blank, solvent control (DMSO).Positive control: 2-AF (2-aminofluorene) 10 μ g/ wares, MMS (methylmethane sulphonic acid ester) 1 μ 1/ ware, Fluorenone (2,4,7-trinitro-9 Fluorenones) 0.2 μ g/ ware, 2-AA 12 μ g/ wares.
2. experimental technique: Salmonella typhimurium, microsomal enzyme flat board mix the warm in advance bath method of mutating experiment.S-9 or PBS (non-S9 contrast) 0.5ml, test sample 100 μ l, bacterium liquid 100 μ l.Positive control (standard mutagen), blank, solvent control (DMSO) mix back 37 ℃ of water-baths vibration 20 minutes.Add 2ml end face agar (0.5mM organizes amino/biotin) again, fast a kind of rhyme scheme in Chinese operas serving as the prelude to a complete score for voices is evenly paved 37 ℃ and is hatched and saw the result in 48 hours.
3. experimental result: selected for use the bacterial strain of two kinds of mutation types of four strains that sample is carried out the test of six dosage in the experiment, metabolism activation+S9 has been arranged or do not having under the condition of metabolism activation-S9 system, test sample does not have tangible inducing action to four kinds of mutants.
Conclusion: under this experimental conditions, in the dosage range of selection, this test sample does not have tangible inducing action to four kinds of mutants.
Five, fed experiment in 30 days
1. materials and methods
Test sample: by embodiment 1 prescription 1 product that makes, crowd's recommended amounts 3.0g/ day is by adult 60kg body weight 0.05g/kgBW.
Laboratory animal: provide Wistar kind body weight 58-79gSPF level ablactation rat and Animal Lab. (moving word 01-4059 number of the quality certification number doctor) by laboratory animal portion of the Capital University of Medical Sciences.Each group, 5 of every treated animals.
Dosage grouping: establish three dosage groups with 100,75 and 50 times of crowd's recommended amounts (0.05g/kgBW), i.e. 5.0g/kgBW, 3.75g/kgBW and 2.50g/kgBW dosage group.Other establishes totally four groups of negative control group (powdery normal feedstuff), each 10 of every treated animal male and female.
Give approach: the blending feedstuff, freely take in.
Feedstuff preparation: as the feedstuff intake, preparation according to dosage contains the feedstuff of different test sample concentration with rat body weight 10%, and promptly 5.0%, 3.75% and 2.50%.
2. experimental result: each treated animal is movable normal at experimental session, and the hair color glossiness is good, ingests and drains normally, finds no symptom and occurs.
Test example 2: bowel relaxing functions zoopery
1. materials and methods
Tried thing: by embodiment 1 prescription 1 product that makes.
Laboratory animal: healthy totally 120 of the level male mices that clean of 18-22g Kunming kind of selecting the department of the Chinese Academy of Sciences of laboratory animal section of portion of Medical School of Peking University (credit number: SCXK-(capital) 2002-0001) breeding for use, wherein 60 are divided into 5 groups, every group 12, a collection of as experiment, carry out the intestinal motility experiment; 60 are divided into 5 groups in addition, 12 every group, as two batches of experiments, carry out the mensuration of defecation time, fecal grains and stool weight.
Dosage: the recommended dose of sample is equivalent to 0.05g/ day/kg body weight for adult (pressing the 60kg weighing machine) 3g every day.5 times, 10 times, 30 times of human body recommended amounts are established in experiment, and promptly every day, 0.25g/kgBW, 1.5g/kgBW were basic, normal, high dosage group.Tried thing with water (sterilizing) preparation, per os gives mice once a day and is tried thing, and the continuous irrigation stomach is measured every index after 10 days.The mouse stomach volume is heavy for the 0.1ml/10g Mus.Establish blank group and model control group simultaneously, water replaces being tried thing, and it is long-pending with respectively to be tried the thing group identical to irritate body of stomach every day.
2. experimental technique:
2.1 the bowel movement test: tried thing continuously after 10 days, each is organized the mice fasting and can't help water 16 hours.Model control group and three dosage groups are irritated stomach and are given the prepared Chinese ink (containing 5% active carbon, 10% Radix Acaciae senegalis) that compound recipe contains corresponding given the test agent, and blank group and model control group are irritated stomach to prepared Chinese ink.Take off cervical vertebra after 25 minutes immediately and put to death animal, open the abdominal cavity and separate mesentery, the clip upper end from pylorus, lower end to the ileocecus intestinal tube, place on the pallet, gently small intestinal is pulled into straight line, measuring intestinal tube length is " small intestinal total length ", is " prepared Chinese ink propelling length " from pylorus to prepared Chinese ink forward position.Be calculated as follows prepared Chinese ink propelling rate:
The prepared Chinese ink propelling rate that draws is carried out data transaction by following formula again,
, P is a prepared Chinese ink propelling rate in the formula, decimally expression.The gained data are measurement data, and under the prerequisite that small intestinal constipation model is set up, the prepared Chinese ink propelling rate of given the test agent group mice is significantly higher than model control group, i.e. this index of decidable positive as a result.
2.2 the mensuration of mice defecation time, fecal grains and stool weight
Tried thing continuously after 10 days, each is organized the mice fasting and can't help water 16 hours.The blank group is given distilled water, and model control group and three dosage groups are irritated stomach and given compound diphenoxylate (10mg/kgBW).Give compound diphenoxylate after 0.5 hour, blank group and model control group mice are irritated stomach with prepared Chinese ink, and the dosage group contains the prepared Chinese ink of given the test agent, and all single cage of animal is raised, normal drinking-water feed.From irritating prepared Chinese ink, write down every first grain of animal and arrange melena grain number and weight in row's melena time and 5 hours.The gained data are measurement data, and under the prerequisite that small intestinal constipation model is set up, first grain row's melena time of given the test agent group mice significantly is shorter than model control group, can judge this index positive as a result.5 hours row's melena grain numbers are apparently higher than model control group, and this index of decidable is the positive as a result.5 hours row's melena weight is apparently higher than model control group, and this index of decidable is the positive as a result.
3. experimental result: what per os gave the mice various dose was tried thing 10 days, with model control group relatively, this is tried thing can increase mice defecation weight (P＜0.05) in the 0.25g/kgBW group; Can improve intestinal motility experiment prepared Chinese ink propelling rate (P＜0.05), shorten mice defecation time (P＜0.01), increase mice defecation weight (P＜0.05) in the 0.50g/kgBW group; Can improve mouse small intestine exercise testing prepared Chinese ink propelling rate (P＜0.01) in the 1.50g/kgBW group, shorten mice defecation time (P＜0.01), increase mice row melena grain number (P＜0.05), increase mice defecation weight (P＜0.01).Being tried thing has no adverse effects to weight of mice.According to " health food check with assessment technique standard " (2003 editions) to the criterion of bowel relaxing functions health food as can be known, the zoopery of given the test agent bowel relaxing functions is the positive as a result.
Test example 3: bowel relaxing functions human feeding trial
1. object and method
1.1 tried thing: by embodiment 1 prescription 1 product that makes.
1.2 reference substance: blank.
1.3 study subject: press the principle of voluntariness and select 18-65 year, constipation person.
1.4 diagnostic criteria: infrequent defecation time lengthening, the big dry and hard or involved and abstruse not smooth functional constipation person of potbellied matter.
1.5 the person's of including in standard:
1.5.1 defecation frequency reduces and feces hardness enhancer.
Be less than 3 times the person week 1.5.2 defecate.
1.5.3 there is not organic constipation person.
1.5.4 habitual constipation person.
1.6 eliminator's standard
1.6.1 the age, gestation or women breast-feeding their children were to these health product allergy sufferers under-18s or over-65s person.
1.6.2 be associated with serious primary disease such as conscience kidney and hemopoietic system, or other accompanying diseases arranged just in therapist, the psychotic.
1.6.3 because of serious structural disease becomes the recent difficult defecation person who causes; The constipation difficulty is with pain person.
1.6.4 do not meet the standard of including in, do not take in accordance with regulations and tried thing, can't judge effect or data not umbra sound effect or safety judgement person.
1.7 EXPERIMENTAL DESIGN and grouping: 100 routine experimenters, be divided into test-meal group and matched group at random, the test-meal group is taken given the test agent, and matched group is a blank.Adopt two kinds of EXPERIMENTAL DESIGN between self and group.
1.8 taking dose and method: the test-meal group is taken given the test agent, every order 2 times, and each 2, took continuously 15 days, the experimenter cuts out medicine or other health product of relevant loosening bowel to relieve constipation at experimental session.
2. experimental result:
2.1100 routine constipation experimenter is divided into test-meal group and matched group at random, test-meal group as a result defecation frequency weekly increases by 2.66 ± 2.31 times, feces character deliquescing 0.90 ± 0.65 degree, defecation condition is improved 1.12 ± 0.87 grades, total effective rate 68.00%, the matched group defecation frequency increases by 0.16 ± 0.74 time, feces character deliquescing 0.04 ± 0.28 degree, defecation condition is improved 0.08 ± 0.40 grade, total effective rate 10.00%.Illustrate that given the test agent has bowel relaxing functions.
2.2 given the test agent has the improvement effect to feeling of fullness, dry stool knot, involved and abstruse symptom such as not smooth.
2.3 before and after the test-meal, hemoglobin, erythrocyte, leukocyte, total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, inosine, carbamide, blood glucose, blood fat and routine urinalysis just routine etc. detect index substantially in normal range, illustrate that this product has no adverse effects to the experimenter is healthy.Do not meet quick after the test-meal and other untoward reaction.
Test example 4: chloasma-dispelling function human feeding trial
1 object and method
1.1 tried thing: by embodiment 1 prescription 1 product that makes.
1.2 reference substance: blank.
1.3 study subject: press the principle of voluntariness and select 18-65 year, chloasma person is arranged.
1.4 diagnostic criteria: facial filbert to dark brown, well-defined patch, symmetry distributes usually, NIP performance and squama, subjective symptomss such as no sufferings.Certain seasonality is arranged, and Xia Chongdong is light.Do not have obvious endocrinopathy, and get rid of the pigmentation that other disease causes.
1.5 the person's of including in standard: all volunteers that chloasma is arranged, all can carry out test-meal through medical fitness and observe.
1.6 eliminator's standard
1.6.1 the age, gestation or women breast-feeding their children were to these health product allergy sufferers under-18s or over-65s person.
1.6.2 be associated with serious primary disease such as conscience kidney and hemopoietic system, or other accompanying diseases arranged just in therapist, the psychotic.
1.6.3 take in a short time or use the article relevant, have influence on hungry judgement person to the result with being tried function.
1.6.4 do not take in accordance with regulations and tried thing, can't judge effect or data not umbra sound effect or safety judgement person.
1.7 EXPERIMENTAL DESIGN and grouping: 100 routine chloasma experimenters, be divided into test-meal group and blank group at random, adopt two kinds of contrast forms between self and group.
1.8 taking dose and method: the test-meal group is taken given the test agent, every day 2 times, and each 2, took continuously 30 days, the experimenter cuts out medicine or other health product and the cosmetics of relevant chloasma at experimental session.Do not change original dietary habit, normal diet.
2. experimental result:
2.1 the chloasma shade changes:
Table 1 chloasma shade changes
| Colour atla (degree) | The example number | Before the test-meal | After the test-meal | Difference |
| Test group | 50 | 1.97±0.49 | 1.47±0.45 | -0.50±0.39**# |
| Matched group | 50 | 1.84±0.35 | 1.81±0.35 | -0.03±0.19 |
Self is #P＜0.05 relatively between * * P＜0.01 group relatively
2.2 chloasma area size variation:
Table 2 chloasma area size variation
| Chloasma area (cm2) | The example number | Before the test-meal | After the test-meal | Difference |
| Test group | 50 | 60.49±37.99 | 49.91±30.46 | -10.58±19.09**# |
| Matched group | 50 | 51.08±29.46 | 51.12±29.19 | 0.04±1.99 |
Self is #P＜0.05 relatively between * * P＜0.01 group relatively
3 conclusions:
3.1 100 routine chloasma experimenters are divided into test-meal group and matched group at random, test-meal group chloasma area on average dwindles 10.58 ± 19.09cm
2(＜0.01), color shoals, colour atla on average reduces by 0.50 ± 0.39 degree (＜0.01), effective 31 examples, total effective rate 62.00%, matched group chloasma area does not have significant change, colour atla on average reduces by 0.03 ± 0.19 degree, effective 2 examples, total effective rate 4.00%, two groups of contrasts have significant difference, illustrate that given the test agent has chloasma-dispelling function.
3.2 given the test agent has the improvement effect to symptoms such as chloasma experimenter's hungry feeling of fatigue, agitation, sleeps.
3.3 before and after the test-meal, routine blood test, routine urinalysis, just routine and blood biochemistry index illustrate that substantially in normal range this product has no adverse effects to the experimenter is healthy.Do not meet quick after the test-meal and other untoward reaction.
Use other formulation product of embodiment of the invention 1-3 to carry out above-mentioned same test, its result of the test basically identical; And when using the mixed extract of more than one Chinese medicines, the proportioning between each raw material of Chinese medicine is little to beneficial effect influence of the present invention, generally adopts the equivalent ratio to be advisable.
Claims (5)
1. compound for the treatment of chloasma and relieving constipation, it is characterized in that forming: Chinese medicine extract 3-50%, oligomeric xylose 10-55%, Semen Vitis viniferae extract 4-20%, soybean extract 2-20%, vitamin C 4-20%, vitamin E 4-20% by following materials of weight proportions, described Chinese medicine extract is the extract of one or more decoction and alcohol sedimentation technique preparation in Flos Rosae Rugosae, Radix Angelicae Sinensis and the Radix Angelicae Dahuricae, the active princlple of described Semen Vitis viniferae extract is a procyanidin, and the active princlple of soybean extract is a soybean isoflavone.
2. a kind of compound for the treatment of chloasma and relieving constipation as claimed in claim 1 is characterized in that the weight proportion of described constitutive material is: Chinese medicine extract 4-40%, oligomeric xylose 10-50%, Semen Vitis viniferae extract 8-19%, soybean extract 5-18%, vitamin C 5-16%, vitamin E 5-15%.
3. a kind of compound for the treatment of chloasma and relieving constipation as claimed in claim 1 is characterized in that the weight proportion of described constitutive material is: Chinese medicine extract 5-25%, oligomeric xylose 30-42%, Semen Vitis viniferae extract 12-18%, soybean extract 9-15%, vitamin C 6-12%, vitamin E 5-10%.
4. as claim 1,2 or 3 described a kind of compounds for the treatment of chloasma and relieving constipation, it is characterized in that described combination dosage form is tablet, granule or capsule.
5. as claim 1, the 2 or 3 described a kind of application of compound in preparation treatment chloasma and relieving constipation medicine or health food that prevent and treat chloasma and relieving constipation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100704156A CN101112466B (en) | 2007-07-31 | 2007-07-31 | Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100704156A CN101112466B (en) | 2007-07-31 | 2007-07-31 | Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101112466A CN101112466A (en) | 2008-01-30 |
| CN101112466B true CN101112466B (en) | 2010-09-22 |
Family
ID=39021095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100704156A Expired - Fee Related CN101112466B (en) | 2007-07-31 | 2007-07-31 | Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101112466B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006920B (en) * | 2011-12-14 | 2015-05-06 | 西安泰科迈医药科技有限公司 | Chloasma-removing pure traditional Chinese medicine composition and preparation method thereof |
| CN103652554B (en) * | 2013-12-04 | 2014-12-17 | 山东龙力生物科技股份有限公司 | Female bowel-relaxing healthful product containing xylooligosaccharide |
| CN105942492A (en) * | 2016-04-28 | 2016-09-21 | 北京珍生康业生物科技有限公司 | Pufanxi capsules (capsules prepared from procyanidine, lycopene, and selenium carrageenan) capable of enhancing anti-oxidation ability of cell membranes and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515251A (en) * | 2003-08-25 | 2004-07-28 | 莉 马 | Composition with function of beautifying face and its application |
| CN1709474A (en) * | 2005-07-14 | 2005-12-21 | 杜越新 | Cosmetic formulation for skin spot-eliminating, whitening and wrinkle-removing, and its preparing method |
-
2007
- 2007-07-31 CN CN2007100704156A patent/CN101112466B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1515251A (en) * | 2003-08-25 | 2004-07-28 | 莉 马 | Composition with function of beautifying face and its application |
| CN1709474A (en) * | 2005-07-14 | 2005-12-21 | 杜越新 | Cosmetic formulation for skin spot-eliminating, whitening and wrinkle-removing, and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101112466A (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101870846B1 (en) | Multi-functional composition and preparation method and application thereof | |
| CN103141709A (en) | Carp feed and preparation method thereof | |
| CN101015603A (en) | Medicine composition with fat-reducing and bowel relaxing functions, preparing process and quality controlling means thereof | |
| CN111202164B (en) | Pet insect-repellent composite soft capsule and preparation method thereof | |
| CN101690584A (en) | Functional food and medicine for clearing throat and preparation method thereof | |
| CN102524639A (en) | Fruit and vegetable fiber chewable tablet with defaecation and health care functions and preparation method thereof | |
| CN106306533A (en) | Traditional Chinese medicine feed for preventing and treating infectious bronchitis and preparation method thereof | |
| CN101946895B (en) | Functional food taking loach as main material and preparation method thereof | |
| CN105168935A (en) | Laxative beautifying healthcare product and manufacturing method thereof | |
| CN101112466B (en) | Compound composition for treating chloasma and stimulating evacuation of the bowels and uses thereof | |
| CN101015618A (en) | Health-care wine with sleeping improving and beauty functions and its preparing process | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN109170916A (en) | One kind keeps fit and healthy food compositions and preparation method thereof | |
| CN104922216A (en) | Bowel-relaxing pharmaceutical composition and preparation method thereof | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN105410941A (en) | Serene Tablet health-care food capable of increasing bone density and strengthening immunity and preparation method thereof | |
| CN105920180A (en) | Health food with efficacy of relaxing bowel and preparation method of health food | |
| CN102028138B (en) | Composition for catharsis and preparation method thereof | |
| CN101810679A (en) | Polyunsaturated fatty acid soft capsule and preparation method thereof | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect | |
| CN104855735A (en) | Feed used for cows postpartum and preparation method thereof | |
| CN102274346B (en) | Medicament or health food composition for preventing hypertension and preparation method and purpose thereof | |
| CN1315411C (en) | Health-care food with functions of relaxing the bowels and beautifying, and its prepn. method | |
| CN114128882A (en) | Desert cistanche probiotic chewable tablet with function of relaxing bowel and preparation method and application thereof | |
| CN101628073B (en) | Preparation used for improving sexual function of male and resisting fatigue and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160623 Address after: Hangzhou City, Zhejiang province 311300 Ling'an City Kam South Street No. 9 Gua fan Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100922 Termination date: 20200731 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |